

Name of the Issue: Gland Pharma Limited

1	Type of Issue	Initial Public Offer
2	Issue Size (Rs. Mn)	64,795.45

Source: Prospectus

3	Grade of issue along with name of the rating agency	
	Name	Not Applicable
	Grade	Not Applicable

4	Subscription Level (Number of times)	2.0337
---	--------------------------------------	--------

Source: Basis of allotment

5 QIB Holding (as a % of Outstanding Capital)

Particulars	%
(i) On Allotment	22.54%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2020)	23.54%
(iii) at the end of 1st FY (March 31, 2021)	23.12%
(iv) at the end of 2nd FY (March 31, 2022)	23.18%
(v) at the end of 3rd FY (March 31, 2023)	27.56%

6 Financials of the issuer

(Rs. million)

Parameters	1st FY (March 31,2021)	2nd FY (March 31,2022)	3rd FY (March 31,2023)
Income from operations	34,628.76	44,007.08	36,246.01
Net Profit for the period	9,969.63	12,116.64	7,810.43
Paid-up equity share capital	163.59	164.30	164.70
Reserves	58,868.83	71,411.91	79,422.52

7 Trading Status

The equity shares of Gland Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2021)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2022)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2023)*	Frequently Traded

* Trading status not disclosed as the relevant fiscal years have not been completed.

Source: Stock exchange websites

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2021)	None	None
(ii) at the end of 2nd FY (March 31, 2022)	Naina Lal Kidwai	Appointed
	Allen Zhang	Appointed
	Yao Fang	Appointed
	Dongming Li	Resigned
	Srinivas Sadu	Re-appointed
(iii) at the end of 3rd FY (March 31, 2023)	Xiaohui Guan	Retired by Rotation
	Yifang Wu	Retired by Rotation

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	Capital Expenditure - Rs. 1,680 Million : Rs. 570 Million and Rs. 1,110 Million to be deployed in fiscals 2021 and 2022 respectively. Working Capital - Rs. 7,695 Million : Rs. 4,348.83 Million and Rs. 3,346.17 Million to be deployed in fiscals 2021 and 2022 respectively. General corporate purposes - Rs. 2,864.68 Million to be deployed in fiscal 2021.
(ii) Actual utilization	Capital Expenditure - Rs. 1,440.04 Million utilized; Working Capital - fully utilised; General Corporate Purpose : fully utilised
(iii) Reasons for deviation, if any	-

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	-
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	-
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	-

Source: Monitoring Agency report

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	1,500.00
Listing Date	20-Nov-20

Price parameters	At close of listing day- November 20, 2020	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2021)		
				Closing price	High	Low
Market Price (BSE)	1,820.45	2,226.50	2,358.05	2,477.80	2,718.65	1,820.45
BSE SENSEX *	43,882.25	46,960.69	51,703.83	49,509.15	52,154.13	27,590.95

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2022)			As at the end of the 3rd FY after the listing of the issue (31st March, 2023)		
	Closing price	High	Low	Closing price	High	Low
Market Price (BSE)	3,269.15	4,316.75	2,469.70	1,268.60	3,443.00	1,155.05
BSE SENSEX *	58,568.51	61,765.59	47,705.80	58,991.52	63,284.19	51,360.42

* Being index of BSE, the designated stock exchange

13 Basis for Issue Price

Not applicable as there are no listed companies in India that engage in a business similar to that of the Company

14 Any other material information

Particulars	Date	Remarks
Listing of equity shares of Gland Pharma Ltd	20-Nov-20	-
Shareholding pattern for period ended November 17, 2020	8-Dec-20	-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2021	22-Oct-21	-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report	25-Oct-21	-
Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI LODR") - Details Of Related Party Transactions	30-Oct-21	-
Announcement under Regulation 30 (LODR)- Change in Directorate	10-Mar-22	-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report	29-Apr-22	-
Board Meeting Outcome for Audited Financial Results (Consolidated and Standalone) for Quarter And financial Year Ended March 31,	19-May-22	-
Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI LODR") - Details Of Related Party Transactions	31-May-22	-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	15-Jun-22	-
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2022	4-Jul-22	-
US FDA Inspection	25-Aug-22	-
Announcement under Regulation 30 (LODR)-Change in Directorate	1-Sep-22	-
Board Meeting Intimation for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2022	10-Oct-22	-
Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022	26-Oct-22	-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	24-Nov-22	-
Clarification sought from Gland Pharma Ltd	29-Nov-22	-
Reply For The Clarification Sought On News Item Appearing In "Media / Publication"	29-Nov-22	-

Announcement under Regulation 30 (LODR)-Acquisition	29-Nov-22	-
Conclusion Of US FDA Inspection At Dundigal Facility, Hyderabad	4-Jan-23	-
Announcement under Regulation 30 (LODR)-Updates on Acquisition	6-Jan-23	-
Board Meeting Intimation for The Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2022	6-Jan-23	-
Board Meeting Outcome for Board Meeting Outcome For Board Meeting Outcome For Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022	23-Jan-23	-
US FDA Inspection	27-Jan-23	-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s	29-Jan-23	-
Clarification sought from Gland Pharma Ltd	20-Apr-23	-
Reply To The Clarification Sought By BSE	20-Apr-23	-
Announcement under Regulation 30 (LODR)-Updates on Acquisition	27-Apr-23	-
Board Meeting Intimation for Board Meeting Intimation For The Approval Of The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2023.	28-Apr-23	-
Audited Financial Results For The Quarter And Year Ended March 31, 2023	18-May-23	-

Note: For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com